The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Showing 1-6 of 6 articles
Optical coherence tomography substudy of a prospective multicentre randomised post-market trial to assess the safety and effectiveness of the Firehawk cobalt-chromium coronary stent (rapamycin target-eluting) system for the treatment of atherosclerotic lesions: TARGET All Comers
Baumbach A,
Lansky A,
Onuma Y,
Asano T,
Johnson TW,
Anderson R,
Kiemeneij F,
Zeng M,
van Royen N,
Slagboom T,
Vlachojannis G,
Serruys PW,
Wijns W
November 20, 2018 | 10.4244/EIJ-D-18-00226
Everolimus-eluting bioresorbable vascular scaffolds for treatment of complex chronic total occlusions
Fam J,
Ojeda S,
Garbo R,
Latib A,
La Manna A,
Vaquerizo B,
Boukhris M,
Vlachojannis G,
van Geuns R,
Ezhumalai B,
Kawamoto H,
van der Sijde J,
Felix C,
Pan M,
Serdoz R,
Boccuzzi G,
De Paolis M,
Sardella G,
Mancone M,
Tamburino C,
Smits PC,
Di Mario C,
Seth A,
Serra A,
Colombo A,
Serruys PW,
Galassi A,
Zijlstra F,
Van Mieghem NM,
Diletti R
June 20, 2017 | 10.4244/EIJ-D-16-00253
Biolimus-eluting versus everolimus-eluting stents in coronary artery disease: a pooled analysis from the NEXT (NOBORI biolimus-eluting versus XIENCE/PROMUS everolimus-eluting stent) and COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) randomised trials
March 20, 2017 | 10.4244/EIJ-D-16-00773
Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with coronary artery disease: three-year follow-up of the COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) trial
Vlachojannis G,
Smits PC,
Hofma S,
Togni M,
Vázquez N,
Valdes M,
Voudris V,
Puricel S,
Slagboom T,
Goy J-J,
den Heijer P,
van der Ent M
July 20, 2015 | 10.4244/EIJV11I3A53
Effect of bivalirudin on aortic valve intervention outcomes study: a two-centre registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty
Kini A,
Yu J,
Cohen M,
Mehran R,
Baber U,
Sartori S,
Vlachojannis G,
Kovacic J,
Pyo R,
O’Neill B,
Singh V,
Jacobs E,
Poludasu S,
Moreno P,
Kim M,
Krishnan P,
Sharma S,
Dangas G
July 21, 2014 | 10.4244/EIJV10I3A54
Latest news
AHEAD OF PRINT
Atherectomy in patients with lower extremity PAD
FREE ARTICLE - Mazen S. Albaghdadi et al
September 25, 2023
AHEAD OF PRINT
De-escalation from ticagrelor to clopidogrel in HBR patients
FREE ARTICLE - Min Chul Kim et al
September 19, 2023
NEW ISSUE
State-of-the-Art on Cerebral Embolic Protection; Debating Guided DAPT; 3-Year Outcomes of the EuroCTO Trial; the Myval Device in Non-Calcified Aortic Regurgitation...
New Issue
September 18, 2023
AHEAD OF PRINT
OCT guidance for evaluation and treatment of the long-term consequences of inadequate ostial left circumflex stenting
Free ARTICLE - Dejan Milasinovic et al
September 7, 2023
AHEAD OF PRINT
DCB in large coronary arteries
FREE ARTICLE - Pier Pasquale Leone et al
September 5, 2023
AHEAD OF PRINT
Rationale and design of the DEDICATE-DZHK6 Trial
FREE ARTICLE - Moritz Seiffert et al
September 1, 2023
AHEAD OF PRINT
DWP for TMVR
FREE ARTICLE - Clément Servoz et al
August 29, 2023